Cargando…
Fenofibrate increases the amount of sulfatide which seems beneficial against Covid-19
Fenofibrate, which is a PPAR-alfpha agonist, increases the level of sulfatide. In this letter we hypothesize on the background of various findings that this is beneficial against COVID-19. Fenofibrate has been used for decades against hypercholesterolemia and has no serious side effects. Therefore,...
Autor principal: | Buschard, Karsten |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier Ltd.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7372998/ https://www.ncbi.nlm.nih.gov/pubmed/32759008 http://dx.doi.org/10.1016/j.mehy.2020.110127 |
Ejemplares similares
-
Uptake of the glycosphingolipid sulfatide in the gastrointestinal tract and pancreas in vivo and in isolated islets of Langerhans
por: Blomqvist, Maria, et al.
Publicado: (2006) -
Sulfatide Preserves Insulin Crystals Not by Being Integrated in the Lattice but by Stabilizing Their Surface
por: Buschard, Karsten, et al.
Publicado: (2016) -
Fenofibrate increases very-long-chain sphingolipids and improves blood glucose homeostasis in NOD mice
por: Holm, Laurits J., et al.
Publicado: (2019) -
Insulin Independence in Newly Diagnosed Type 1 Diabetes Patient following Fenofibrate Treatment
por: Buschard, Karsten, et al.
Publicado: (2020) -
The repertoire of protein-sulfatide interactions reveal distinct modes of sulfatide recognition
por: Capelluto, Daniel G. S
Publicado: (2022)